Charles Crump
Internal Medicine · Chattanooga, TNNPI 1093704744
Payments from drug & device makers
Across 667 payments — averaging $1519.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$541K
- Novo Nordisk AS$300K
- AbbVie$129K
- Kowa Research Institute, Inc.$31K
- Alnylam Pharmaceuticals Inc.$11K
- Novo Nordisk$154
- plus $479 from 15 others
What the payments were for
- Food & beverage$702100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 71 | $541,402 |
| Novo Nordisk AS | 498 | $299,694 |
| AbbVie | 27 | $129,094 |
| Kowa Research Institute, Inc. | 24 | $31,441 |
| Alnylam Pharmaceuticals Inc. | 2 | $11,098 |
| Novo Nordisk | 15 | $154 |
| Novartis | 4 | $78 |
| Amgen | 4 | $73 |
| Boehringer Ingelheim | 4 | $55 |
| Abbott | 2 | $41 |
| AstraZeneca | 3 | $38 |
| Amarin Pharma, Inc. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Pfizer | 2 | $24 |
| Eisai Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Medtronic | 1 | $13 |
| GSK | 1 | $12 |
| Boston Scientific | 1 | $11 |
How this compares
$1,013,363 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 13 | $4,129 |
| Esomeprazole Magnesium | 34 | $2,977 |
| Novolog FlexpenInsulin Aspart | 17 | $2,806 |
| ValacyclovirValacyclovir Hcl | 28 | $2,134 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 22 | $1,905 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,410 |
| Atorvastatin Calcium | 76 | $1,127 |
| Rosuvastatin Calcium | 90 | $1,051 |
| Testosterone Cypionate | 20 | $1,042 |
| Ezetimibe | 24 | $944 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 35 | $784 |
| Metoprolol Succinate | 37 | $755 |
| Levothyroxine Sodium | 86 | $753 |
| Losartan Potassium | 63 | $720 |
| SynthroidLevothyroxine Sodium | 11 | $716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta | $12 | $4,12913 claims |
| AbbVieSynthroid | $129,094 | $71611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Chattanooga
- Mark McKenzieChattanooga$11.9M
- Eugene RyanChattanooga$636K
- Valerie BoazChattanooga$105K
- Carlton VollbergChattanooga$105K
- Maighan SeagroveChattanooga$78K
- Jeremy HogstromChattanooga$30K
- Jermaine HogstromChattanooga$29K
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.